Warsaw - Delayed Quote PLN
Bioceltix S.A. (BCX.WA)
117.40
+1.40
+(1.22%)
As of 10:00:13 AM GMT+2. Market Open.
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in PLN.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Lukasz Bzdzion | President of the Management Board | 367.52k | -- | -- |
| Dr. Pawel Wielgus | Member of the Management Board | 359.13k | -- | -- |
| Andrij Wlach | Chief Financial Officer | -- | -- | -- |
| Mr. Grzegorz Ostropolski | Chief Operating Officer | -- | -- | -- |
| Dr. Jakub Grzesiak Ph.D. | Technology Director | -- | -- | -- |
Bioceltix S.A.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 27
Description
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.
Corporate Governance
Bioceltix S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available
Related Tickers
ALZN Alzamend Neuro, Inc.
0.6620
-2.69%
ZVSA ZyVersa Therapeutics, Inc.
0.6751
-3.69%
XLO Xilio Therapeutics, Inc.
0.7852
-5.23%
MNPR Monopar Therapeutics Inc.
40.81
-4.45%
ADAP Adaptimmune Therapeutics plc
0.2771
+4.45%
BCAB BioAtla, Inc.
0.4449
+0.98%
CABA Cabaletta Bio, Inc.
1.3100
+3.15%
RNA Avidity Biosciences, Inc.
31.21
+1.18%
CRMD CorMedix Inc.
9.06
-0.44%
DNA Ginkgo Bioworks Holdings, Inc.
8.02
+2.30%